


Global guidance framework for the responsible use of the life sciences

Mitigating biorisks and governing
dual-use research



Global guidance framework for the responsible use of the life sciences

Mitigating biorisks and governing
dual-use research

Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research

ISBN 978-92-4-005610-7 (electronic version)
ISBN 978-92-4-005611-4 (print version)

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research. Geneva: World Health Organization; 2022. Licence: [CC BY-NC-SA 3.0 IGO](#).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

<i>Foreword</i>	<i>vi</i>
<i>Acknowledgements</i>	<i>viii</i>
<i>Abbreviations and acronyms</i>	<i>xvi</i>
<i>Glossary</i>	<i>xviii</i>
<i>Executive summary</i>	<i>xxiv</i>

Section 1. Introduction	1
1.1 Context	2
1.2 Rationale for this global guidance framework.....	6
1.3 Aims and scope.....	8
1.4 Audiences	10
1.5 Methodology	12
1.6 Implementation and review	14

Section 2. Evolving challenges and gaps in the governance of biorisks	15
2.1 Increasing pace of advances in the life sciences	17
2.2 Identifying and managing potential risks	20
2.3 Persistent lack of awareness.....	28
2.4 Attending gaps in biorisk governance	30
2.5 Updating terminologies and framing.....	33

Section 3. Values and principles to guide governance of biorisks	37
3.1 Governance for the responsible use of the life sciences.....	39
3.2 Values and principles to guide the governance of biorisks.....	42

Section 4. Tools and mechanisms for the governance of biorisks	47
4.1 Elements of biorisk governance	49
4.2 A comprehensive governance approach to biorisk management	53
4.3 Biorisk governance tools and mechanisms for different stakeholders.....	57
4.3.1 Stakeholder: national governments	59
4.3.2 Stakeholder: scientists.....	61
4.3.3 Stakeholder: research institutions	63
4.3.4 Stakeholder: funding bodies.....	64
4.3.5 Stakeholder: publishers and editors.....	66
4.3.6 Stakeholder: standard-setting institutions.....	67
4.3.7 Stakeholder: educators	68
4.3.8 Stakeholder: international organizations.....	69
4.3.9 Stakeholder: civil society networks and publics	70
4.3.10 Stakeholder: private sector	71
4.4 Awareness raising, education, training and capacity-building	73
4.4.1 Examples of awareness raising, education, training and capacity-building	73
4.4.2 Lessons from past activities.....	74
Section 5. The framework in action	76
5.1 Implementing the framework.....	79
5.2 Key considerations for Member States	81
5.3 Key considerations for other stakeholders	87
Section 6. Conclusions	111
References	114
Annex 1. Scenarios.....	119
Introduction.....	119
Scenario 1. Gene therapy	121
Scenario 2. Neurobiology	126
Scenario 3. DNA synthesis	131
Scenario 4. Mutational scanning.....	142
Scenario 5. Mobile public health laboratory	148
Scenario 6. Gene drive	154
Scenario 7. International collaboration on high-consequence pathogens research	160

Annex 2. Case studies for responsible life sciences research on high-consequence pathogens	167
Case study 1. Chemical synthesis of poliovirus cDNA	168
Case study 2. 1918 Spanish influenza reconstruction	172
Case study 3. Environmental surveillance for Nipah virus.....	177

Annex 3. Illustrative examples of awareness raising, education, training and capacity-building in the life sciences and related fields.....	180
--	------------

BOXES

Box 1. Examples of documents and tools for identifying or managing dual-use research, listed by year of publication.....	22
Box 2. Foresight and biorisk management: role and methods	25
Box 3. A comprehensive biorisk management framework.....	56
Box 4. Lessons from past efforts in awareness raising, education, training and capacity-building	74
Box 5. Checklist for national governments	83
Box 6. Checklist for scientists.....	87
Box 7. Checklist for research institutions.....	91
Box 8. Checklist for funding bodies.....	95
Box 9. Checklist for publishers and editors	98
Box 10. Checklist for civil society networks and publics.....	102
Box 11. Checklist for the private sector	106


TABLES

Table 1. Values and principles for safe, secure and responsible use of the life sciences	44
Table 2. Examples of tools and mechanisms of biorisk governance.....	51
Table 3. An illustrative framework for systematically evaluating tools and mechanisms towards a comprehensive governance approach for biorisk management	54

FIGURE

Fig. 1. A stepwise approach for implementing the framework and developing biorisk management activities	78
--	-----------

Foreword



Life sciences and technologies can offer endless opportunities to improve our health, our societies and our environment. However, developments and advances in life sciences and associated technologies may pose risks that include safety and security risks caused by accidents, inadvertent and deliberate misuse to cause harm. For example, advances in synthetic biology can have beneficial applications in medicine, energy, and environmental remediation but can also raise safety and security concerns by enhancing the pathogenic characteristics of ordinary organisms, creating new pathogens from synthetic DNA or reconstructing extinct pathogens. Development in neurosciences can help preventing and treating neurological disorders such as Parkinson's disease and Alzheimer's disease, but new knowledge and applications can also create new risks, including those of manipulating the way we think, move or behave. These risks arising from developments in the life sciences and converging technologies need to be recognized and mitigated. This is the objective of this framework. The values, principles, tools and mechanisms described in this framework aim to support Member States and stakeholders to prevent and mitigate biorisks and govern dual-use research.

WHO plays a critical role in harnessing the power of science and innovation and provides global leadership to support Member States in translating the latest in science, evidence, innovation and digital solutions to improve health and health equity for all.

Ensuring that WHO anticipates and stays on top of the latest scientific

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_31709

